PCP Considerations for Improving Asthma Care

Format: Webcourse
Credit(s): 1.00 (60 min)
Release Date: Jun 15, 2020
Expiration Date: Jun 15, 2021
Credit Type(s):
  • CME / AMA PRA Category 1 Credit™
  • MOC / ABIM MOC Part 2 Credit

PROGRAM OVERVIEW

Asthma, a chronic inflammatory airway condition, is a leading cause of morbidity and mortality, accounting for 1 of every 250 deaths each year. A growing understanding of asthma phenotypes and endotypes has led to the development of targeted treatment options. However, it remains challenging to properly evaluate patients with asthma, categorize them, and then select appropriate targeted therapy. In addition, patient nonadherence to prescribed asthma regimens remains an issue.

This activity, PCP Considerations for Improving Asthma Care, will provide primary care clinicians with the most up-to-date understanding of asthma phenotypes and endotypes. The education will review the agents recently made available to manage asthma, as well as those in late-stage development. In addition, strategies for improving patient adherence to asthma medications will be examined.

AGENDA

Welcome and Introduction
Ensuring Timely Asthma Diagnoses, Assessments, and Management
PCP‐driven Tactics to Improve Asthma Therapy Adherence and Use
Understanding the Growing Asthma Treatment Arsenal
Conclusions

TARGET AUDIENCE

This activity is intended for primary care physicians, the frontline clinicians responsible for the timely management and education of adults with asthma.

EDUCATIONAL OBJECTIVES

This program is designed to address ACGME and IOM competencies, including delivering patient-centered care, practicing evidence-based medicine, and focusing on quality improvement.

At the conclusion of this activity, participants should be able to:

  • Classify patients with asthma based on disease presentation, severity, and endotype
  • Implement PCP-driven strategies to promote asthma medication adherence and proper inhaler use
  • Evaluate the most recent safety and efficacy data for the newer asthma armamentarium
  • Incorporate newer asthma therapies into appropriate care plans

ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of USF Health and Rockpointe. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

USF Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the CME accreditation of this program, please email: cpdsupport@usf.edu.

FACULTY

Praveen Akuthota, MD
Associate Professor of Medicine
University of California-San Diego
San Diego, CA
Praveen Akuthota, MD is an Associate Professor of Medicine in the Division of Pulmonary, Critical Care, and Sleep Medicine at the University of California-San Diego. Dr. Akuthota’s research efforts range from basic scientific investigations of human eosinophil biology and eosinophilic inflammation to clinical and translational efforts in asthma and eosinophilic pulmonary disease. He is the corresponding Principal Investigator for the UCSD Clinical Center in the National Heart, Lung, and Blood Institute’s PrecISE Network that will be studying precision interventions in severe asthma. He is a co-investigator on a study published in the New England Journal of Medicine showing the efficacy of anti-IL-5 therapy in the treatment of the eosinophilic disease EGPA (Churg-Strauss syndrome). His research group is involved in other multicenter studies in eosinophilic disease and asthma.

Basic science investigations from Dr. Akuthota focus on ex vivo studies of human eosinophils and include published work studying eosinophil trafficking and studying microparticle release by eosinophils. He has written several reviews and chapters discussing eosinophil immunobiology and clinical considerations in eosinophilic diseases. Dr. Akuthota is an At-Large Member of the Board of Directors of the International Eosinophil Society (www.eosinophil-society.org).
Wanda Phipatanakul, MD, MS
Professor of Pediatrics
Harvard Medical School
Director, Asthma Clinical Research Center
Boston Children's Hospital
Boston, MA
Wanda Phipatanakul, MD, MS is Director of the Asthma Clinical Research Center at Boston Children’s Hospital and Professor of Pediatrics at Harvard Medical School. She has dedicated her career to reducing and preventing asthma and allergic diseases.

Originally from St. Louis, she earned her medical degree from Loma Linda University and completed her residency in pediatrics at Children’s Hospital Los Angeles in 1997. After a fellowship in immunology at Johns Hopkins University, she joined the faculty in the Division of Immunology and Allergy at Boston Children’s and Harvard Medical School, where she has remained for the past 19 years.

Dr. Phipatanakul has built a deep network of community relationships and conducts both school- and home-based asthma studies in children. She has also had continuous National Institutes of Health (NIH) funding for nearly 20 years. She leads the National Institute of Allergy and Infectious Diseases (NIAID) School Inner-City Asthma Intervention Study and the National Heart, Lung, and Blood Institute (NHLBI) Environment Assessment of Sleep in Youth. She is the overall Principal Investigator for an NIAID-funded, nationwide, multicenter asthma-prevention study evaluating omalizumab (anti-IgE) in preventing the atopic march and asthma.

Most recently, Dr. Phipatanakul was awarded an NIAID U01 evaluating whether patients carrying an IL4RαR576gene variant will have a greater response to dupilumab. She leads her Center as Pediatric PI in multiple NHLBI asthma and prevention networks, including Precise, and has authored more than 220 publications in scientific journals, including JAMA and the New England Journal of Medicine. She is passionate about successfully mentoring the next generation of investigators, serving the American Academy of Allergy, Asthma & Immunology (AAAAI) and the American Board of Allergy and Immunology (ABAI) in support of her specialty, and serving as a role model to others balancing work and family.

ABIM MOC DESIGNATION STATEMENT



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive CME credit and/or MOC points, you MUST pass the post-test with a score of ≥(75 )% and complete the evaluation. For ABIM MOC points, you agree to provide permission to have your information shared with the ABIM through USF Health’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

AAFP CREDIT DESIGNATION


This Enduring Material activity, PCP Considerations for Improving Asthma Care, has been reviewed and is acceptable for up to 1.00 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 06/15/2020. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLAIMER

The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

EOE/ADA

USF Health is an Equal Opportunity/ Affirmative Action/ Equal Access Institution.

NON-ENDORSEMENT

USF Health does not endorse any product, material, or service mentioned in association with this activity.

POTENTIAL CONFLICTS OF INTEREST

USF Health endorses the standards of the ACCME that require everyone in a position to control the content of an accredited educational activity to disclose all financial relationships with commercial interests that are related to the content of the educational activity. All accredited activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when individuals in a position to control the content of an accredited educational activity have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

USF Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Faculty Disclosures

The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Praveen Akuthota, MD: Advisory Board/ Research: AstraZenca, GlaxoSmithKline; Consultant: AstraZeneca

Wanda Phipatanakul, MD, MS: Advisory Board/Grant/Research Consultant: Genentech, Novartis, Regeneron, Sanofi

Non-faculty Content Contributors Disclosures

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Terry Ann Glauser, MD, MPH; Shanu Gupta, MD; Karim Hanna, MD; USF Health CPD staff: Nothing to disclose

FDA DISCLOSURE

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

SYSTEM REQUIREMENTS

In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an internet browser capable of playing an HTML5 video.

INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME/AAFP CREDIT/MOC POINTS​

There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test, with a score of 75% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test two times.

PROVIDER

Jointly provided by USF Health and Rockpointe

Physician CME

SUPPORTER

This educational activity is supported by an educational grant from GlaxoSmithKline.

RELATED COURSES

Asthma Management in the Era of Targeted Therapy: Using Phenotype and Biomarkers to Individualize Management

Learn More

Vaping and Teens: Strategies to Help Stem the Tide

Learn More

Vaping and Teens: Strategies to Help Stem the Tide

Credits 1.00 (60 min)

Format Webcourse

Opioid Analgesics: Risk Evaluation and Mitigation Strategy (REMS) and the New FDA Blueprint

Learn More
This entry was posted in . Bookmark the permalink.

Follow Us :

Follow Us :

© 2021 Rockpointe Corporation

Privacy Policy

© 2021 Rockpointe Corporation

Privacy Policy